Gathering the record
Relay is organizing the evidence and source boundaries.
Investigational amylin/GLP-1-GIP peptide combination
An experimental weight-loss combination of petrelintide and CT-388, also called enicepatide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
The ZYNERGY Phase 2 trial directly registers the combination, but no results were posted at Relay’s evidence cutoff.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
A registered Phase 2 study directly evaluates the pairing, making the relationship more than conceptual. Until results are reported, efficacy and safety conclusions still come only from separate component programs and cannot establish what the combination does.
Registered study — no resultsMechanism, biomarker change, and clinical benefit are different evidence questions.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational fixed research combination; a direct combination trial is registered, with no posted outcome results at the cutoff. Whether the complete combination improves outcomes beyond either component and how overlapping appetite, gastrointestinal, metabolic, and body-composition effects change safety.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
NCT07589686 registers weekly petrelintide plus enicepatide (CT-388), but its public arm descriptions do not disclose numerical combination doses. Individual drug doses cannot fill that gap.
What would fill this gap: A public numerical combination protocol or primary results report for this exact pairing.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
An official Phase 2 registry directly identifies the petrelintide and CT-388 combination in adults with obesity, but no outcome results were available at Relay's evidence cutoff.
Population: Adults with obesity
Design: Registered interventional trial
Mechanisms
A registered Phase 2 study directly evaluates the pairing, making the relationship more than conceptual. Until results are reported, efficacy and safety conclusions still come only from separate component programs and cannot establish what the combination does.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Direct registered-combination evidence with no outcome results; component programs cannot substitute for combination findings.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether the complete combination improves outcomes beyond either component and how overlapping appetite, gastrointestinal, metabolic, and body-composition effects change safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Registration confirms that the combination is being studied; it does not establish benefit, safety, or compatibility. Component studies cannot supply a combination schedule, interaction conclusion, or preparation standard. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Registered interventional trial
Adults with obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
NCT07589686
NCT06054854
NCT06451653